Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01208090 | ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis | PHASE2 | COMPLETED | 326 | — | — | Oct 31, 2010 | Nov 30, 2012 | Mar 30, 2025 | 67 | Austria, Belgium +15 |
| Arm | Type | Description |
|---|---|---|
| Investigational drug - Dose 1 | EXPERIMENTAL | - |
| Investigational drug - Dose 2 | EXPERIMENTAL | - |
| Matching placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ACT-128800 | DRUG | ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily |
| Placebo | DRUG | ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily |
Inclusion Criteria: * Adult males and females aged 18 to 60 years (inclusive) with moderate to severe chronic plaque psoriasis who require systemic treatment. Exclusion Criteria: * Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than ps...